Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of ART-123 for DIC Caused by Hematologic Malignancies or Infections
jRCT2080220059Phase 3
- Sponsor
- Asahi Kasei Pharma
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of thrombomodulin alfa in disseminated intravascular coagulation (DIC), hematopoietic malignancies and Infection, sponsored by Asahi Kasei Pharma.
02
Drugs
thrombomodulin alfa
03
Conditions
disseminated intravascular coagulation (DIC)hematopoietic malignanciesInfection
Beyond the preview
Go deeper on jRCT2080220059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220059.